BiotechTube

Hetrombopag Olamine

Phase 1Completed
3 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immune Thrombocytopenia

Conditions

Immune Thrombocytopenia

Trial Timeline

Jul 14, 2018 → Aug 17, 2018

NCT ID
NCT03603132

About Hetrombopag Olamine

Hetrombopag Olamine is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Immune Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03603132. Target conditions include Immune Thrombocytopenia.

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenia were approved

Approved (7) Terminated (2) Active (13)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅IgPro10CSLApproved
✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved
✅Methylprednisolone + PrednisoloneBiogenApproved
✅Flebogamma 5% DIFGrifolsApproved
✅Asceniv™ADMA BiologicsApproved
✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT05944211Phase 2Recruiting
NCT03977805Phase 1Completed
NCT03603132Phase 1Completed
NCT03557099Phase 1/2Completed
NCT02614846Phase 1UNKNOWN
NCT02403440Phase 1UNKNOWN
NCT02409394Phase 1Completed

Competing Products

20 competing products in Immune Thrombocytopenia

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SatralizumabChugai PharmaceuticalPhase 3
47
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
RomiplostimKyowa KirinPhase 1/2
32
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
40
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
HerombopagJiangsu Hengrui MedicinePhase 3
36
Zostavax®MerckPre-clinical
18
Raltegravir + AtazanavirMerckPre-clinical
26
ZostavaxMerckPre-clinical
26
MK-8723 + Matching PlaceboMerckPhase 1
29
Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXMNovartisPhase 2
35